State Street Corp. Updates Passive Stake in Atara Biotherapeutics
Ticker: ATRA · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**State Street is still holding Atara Bio shares, no big changes here.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Atara Biotherapeutics Inc. common stock as of December 31, 2023. This filing is an update to their previous disclosures, confirming their continued passive investment in Atara Biotherapeutics. For investors, this means a significant institutional holder maintains its position, which can be seen as a vote of confidence, but it doesn't signal any new strategic moves or changes in ownership percentage from this specific filing.
Why It Matters
This filing confirms a major institutional investor, State Street Corporation, continues to hold shares in Atara Biotherapeutics, which can provide a level of stability and institutional backing for the stock.
Risk Assessment
Risk Level: low — This is a routine amendment by a passive institutional investor and does not indicate any immediate risk or significant change in the company's outlook.
Analyst Insight
An investor should note that State Street Corporation continues to hold a passive stake in Atara Biotherapeutics, which is a routine update and doesn't suggest any immediate buy or sell action based solely on this filing. It confirms institutional interest but provides no new directional insight.
Key Players & Entities
- State Street Corporation (company) — the reporting person filing the SC 13G/A
- Atara Biotherapeutics, Inc. (company) — the subject company whose common stock is being reported
- 04-2456637 (number) — State Street Corporation's IRS Identification No.
- 046513107 (number) — the CUSIP number for Atara Biotherapeutics Inc. common stock
- December 31, 2023 (date) — the date of the event requiring the filing of this statement
- January 22, 2024 (date) — the filing date of the SC 13G/A
FAQ
What is the purpose of this SC 13G/A filing?
This SC 13G/A is an amendment to a previous Schedule 13G filing, indicating an update to State Street Corporation's ownership information regarding Atara Biotherapeutics Inc. common stock as of December 31, 2023.
Who is the reporting person in this filing?
The reporting person is State Street Corporation, with IRS Identification No. 04-2456637, located at 1 Congress Street, Suite 1, Boston, MA 02114.
What is the subject company of this filing?
The subject company is Atara Biotherapeutics, Inc., whose common stock is being reported. Its CUSIP number is 046513107.
What was the 'date of event' that triggered this filing?
The 'date of event which requires filing of this statement' was December 31, 2023, which is typically the end of the fiscal year for many institutions.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13D-1(B), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding Atara Biotherapeutics, Inc. (ATRA).